Patents by Inventor Jonas MALMBORG

Jonas MALMBORG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NMDA ANTAGONIST PRODRUGS
    Publication number: 20210040039
    Abstract: Prodrugs of an NMDA antagonist, (S)-1-phenyl-2-(pyridin-2-yl)ethanamine, useful for the treatment of depression (particularly major depressive disorder) or pain; compositions comprising them, and methods of making them.
    Type: Application
    Filed: October 26, 2020
    Publication date: February 11, 2021
    Inventors: Gunnar Nordvall, Katharina Högdin, Per Jonas Malmborg, Annika Kers, Dirk Reinhold Weigelt, Peter Robert Bernstein, Michael Quirk, Michael Balestra
  • NMDA antagonist prodrugs
    Patent number: 10815199
    Abstract: Prodrugs of an NMDA antagonist, (S)-1-phenyl-2-(pyridin-2-yl)ethanamine, useful for the treatment of depression (particularly major depressive disorder) or pain; compositions comprising them, and methods of making them.
    Type: Grant
    Filed: January 20, 2019
    Date of Patent: October 27, 2020
    Assignee: AstraZeneca AB
    Inventors: Gunnar Nordvall, Katharina Högdin, Per Jonas Malmborg, Annika Kers, Dirk Reinhold Weigelt, Peter Robert Bernstein, Michael Quirk, Michael Balestra
  • NMDA ANTAGONIST PRODRUGS
    Publication number: 20190152914
    Abstract: Prodrugs of an NMDA antagonist, (S)-1-phenyl-2-(pyridin-2-yl)ethanamine, useful for the treatment of depression (particularly major depressive disorder) or pain; compositions comprising them, and methods of making them.
    Type: Application
    Filed: January 20, 2019
    Publication date: May 23, 2019
    Inventors: Gunnar Nordvall, Katharina Högdin, Per Jonas Malmborg, Annika Kers, Dirk Reinhold Weigelt, Peter Robert Bernstein, Michael Quirk, Michael Balestra
  • NMDA antagonist prodrugs
    Patent number: 10207994
    Abstract: Prodrugs of an NMDA antagonist, (S)-1-phenyl-2-(pyridin-2-yl)ethanamine, useful for the treatment of depression (particularly major depressive disorder) or pain; compositions comprising them, and methods of making them.
    Type: Grant
    Filed: October 17, 2017
    Date of Patent: February 19, 2019
    Assignee: AstraZeneca AB
    Inventors: Gunnar Nordvall, Katharina Högdin, Per Jonas Malmborg, Annika Kers, Dirk Reinhold Weigelt, Peter Robert Bernstein, Michael Quirk, Michael Balestra
  • NMDA ANTAGONIST PRODRUGS
    Publication number: 20180037550
    Abstract: Prodrugs of an NMDA antagonist, (S)-1-phenyl-2-(pyridin-2-yl)ethanamine, useful for the treatment of depression (particularly major depressive disorder) or pain; compositions comprising them, and methods of making them.
    Type: Application
    Filed: October 17, 2017
    Publication date: February 8, 2018
    Inventors: Gunnar Nordvall, Katharina Högdin, Per Jonas Malmborg, Annika Kers, Dirk Reinhold Weigelt, Peter Robert Bernstein, Michael Quirk, Michael Balestra
  • NMDA antagonist prodrugs
    Patent number: 9822075
    Abstract: Prodrugs of an NMDA antagonist, (S)-1-phenyl-2-(pyridin-2-yl)ethanamine, useful for the treatment of depression (particularly major depressive disorder) or pain; compositions comprising them, and methods of making them.
    Type: Grant
    Filed: October 30, 2014
    Date of Patent: November 21, 2017
    Assignee: AstraZeneca AB
    Inventors: Gunnar Nordvall, Katharina Hogdin, Per Jonas Malmborg, Annika Kers, Dirk Reinhold Weigelt, Peter Robert Bernstein, Michael Quirk, Michael Balestra
  • Triazole compounds and their use as gamma secretase modulators
    Patent number: 9718805
    Abstract: The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof. The invention also relates to pharmaceutical compositions comprising these compounds, to processes for making these compounds, and to their use as medicaments for treatment and/or prevention of A?-related diseases.
    Type: Grant
    Filed: June 3, 2014
    Date of Patent: August 1, 2017
    Assignee: Acturum Life Science AB
    Inventors: Yevgeni Besidski, Ulrika Yngve, Kim Paulsen, Christian Erik Linde, Jonas Malmborg
  • Triazole compounds and their use as gamma secretase modulators
    Patent number: 9611254
    Abstract: The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof. The invention also relates to pharmaceutical compositions comprising these compounds, to processes for making these compounds, and to their use as medicaments for treatment and/or prevention of A?-related diseases.
    Type: Grant
    Filed: June 3, 2014
    Date of Patent: April 4, 2017
    Assignee: Acturum Life Science AB
    Inventors: Yevgeni Besidski, Ulrika Yngve, Kim Paulsen, Christian Erik Linde, Gunnar Nordvall, Istvan Macsari, Jonas Malmborg
  • NMDA ANTAGONIST PRODRUGS
    Publication number: 20160280647
    Abstract: Prodrugs of an NMDA antagonist, (S)-1-phenyl-2-(pyridin-2-yl)ethanamine, useful for the treatment of depression (particularly major depressive disorder) or pain; compositions comprising them, and methods of making them.
    Type: Application
    Filed: October 30, 2014
    Publication date: September 29, 2016
    Inventors: Gunnar Nordvall, Katharina Högdin, Per Jonas Malmborg, Annika Kers, Dirk Reinhold Weigelt, Peter Robert Bernstein, Michael Quirk, Michael Balestra
  • Pyrimidine compounds and their use as gamma secretase modulators
    Patent number: 9439904
    Abstract: The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof. The invention also relates to pharmaceutical compositions comprising these compounds, to processes for making these compounds, and to their use as medicaments for treatment and/or prevention of A?-related diseases.
    Type: Grant
    Filed: June 3, 2014
    Date of Patent: September 13, 2016
    Assignee: Acturum Life Science AB
    Inventors: Yevgeni Besidski, Ulrika Yngve, Kim Paulsen, Christian Erik Linde, Istvan Macsari, Jonas Malmborg, Alexander Paptchikhine, Per Arvidsson
  • PYRIMIDINE COMPOUNDS AND THEIR USE AS GAMMA SECRETASE MODULATORS
    Publication number: 20160129002
    Abstract: The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof. The invention also relates to pharmaceutical compositions comprising these compounds, to processes for making these compounds, and to their use as medicaments for treatment and/or prevention of A?-related diseases.
    Type: Application
    Filed: June 3, 2014
    Publication date: May 12, 2016
    Applicant: Acturum Life Science AB
    Inventors: Yevgeni BESIDSKI, Ulrika YNGVE, Kim PAULSEN, Christian Erik LINDE, Istvan MACSARI, Jonas MALMBORG, Alexander PAPTCHIKHINE, Per ARVIDSSON
  • TRIAZOLE COMPOUNDS AND THEIR USE AS GAMMA SECRETASE MODULATORS
    Publication number: 20160122326
    Abstract: The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof. The invention also relates to pharmaceutical compositions comprising these compounds, to processes for making these compounds, and to their use as medicaments for treatment and/or prevention of A?-related diseases.
    Type: Application
    Filed: June 3, 2014
    Publication date: May 5, 2016
    Inventors: Yevgeni BESIDSKI, Ulrika YNGVE, Kim PAULSEN, Christian LINDE, Gunnar NORDVALL, Istvan MACSARI, Jonas MALMBORG
  • TRIAZOLE COMPOUNDS AND THEIR USE AS GAMMA SECRETASE MODULATORS
    Publication number: 20160108022
    Abstract: The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof. The invention also relates to pharmaceutical compositions comprising these compounds, to processes for making these compounds, and to their use as medicaments for treatment and/or prevention of A?-related diseases.
    Type: Application
    Filed: June 3, 2014
    Publication date: April 21, 2016
    Inventors: Yevgeni BESIDSKI, Ulrika YNGVE, Kim PAULSEN, Christian Erik LINDE, Jonas MALMBORG